MannKind Data at HFSA 2026 Highlights New Evidence Supporting Furoscix ReadyFlow™ for the Outpatient Management of Edema in Heart Failure (HF) and Chronic Kidney Disease (CKD)
Key Highlights
- ➤Furoscix ReadyFlow matched IV furosemide bioequivalence and produced comparable diuretic responses
- ➤Relative bioavailability reached 91.3% thigh and 92.7% upper-arm injection sites
- ➤Comparable responses versus Furoscix On-body Infusor support transition to ReadyFlow
- ➤FDA approved Furoscix ReadyFlow in July 2026 for HF- or CKD-related fluid overload
- ➤ReadyFlow delivers an 80 mg/mL dose through autoinjector administration in under 10 seconds
Expert Statements
Ajay Ahuja, Chief Medical Officer of MannKind Corporation
“As healthcare providers seek ways to manage worsening congestion earlier and outside the hospital setting, these data add to the growing body of evidence supporting Furoscix ReadyFlow as an important treatment option for patients with heart failure or chronic kidney disease”
Ajay Ahuja, Chief Medical Officer of MannKind Corporation
“The findings presented at the HFSA ASM reinforce the consistent pharmacologic performance of Furoscix ReadyFlow while demonstrating flexibility that may help clinicians incorporate this innovative therapy into patient care.”
Michael Castagna, Chief Executive Officer of MannKind Corporation
“Patients living with heart failure and chronic kidney disease often experience recurrent episodes of worsening fluid overload that can lead to emergency department visits and hospitalization”
Michael Castagna, Chief Executive Officer of MannKind Corporation
“With the recent launch of Furoscix ReadyFlow, healthcare providers now have access to a new autoinjector-based treatment option designed to deliver IV-equivalent diuretic therapy in seconds.”
Michael Castagna, Chief Executive Officer of MannKind Corporation
“These data presented at HFSA reinforce our commitment to advancing innovative solutions that may help patients receive treatment earlier and outside traditional hospital settings.”
* New analyses on Furoscix ReadyFlow PK/PD performance delivered via an autoinjector demonstrated comparable urine output to IV furosemide * Consistent bioavailability, diuresis and natriuresis across injection sites support flexible administration in clinical practice * Cross-study analysis demonstrates comparable diuretic and natriuretic responses between Furoscix ReadyFlow and Furoscix(®) (furosemide) On-body Infusor, supporting a seamless transition to ReadyFlow * Data presentations build on the July 2026 FDA approval and U.S. launch of Furoscix ReadyFlow, the first and only autoinjector delivering IV-equivalent diuretic therapy for heart failure- and CKD-related edema (fluid overload) WESTLAKE VILLAGE, Calif., Oct. 09, 2026 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a biopharmaceutical company dedicated to transforming chronic disease care through innovative, patient-centric solutions for cardiometabolic and orphan lung diseases, today announced new clinical data related to Furoscix ReadyFlow (furosemide injection) that will be presented at the Heart Failure Society of America (HFSA) Annual Scientific Meeting (ASM) 2026, taking place October 9-12, 2026, in Phoenix.
Get started
Create a free account to read the full story.